VANTABIO.BO · BSE
Vanta Bioscience Limited
₹20.58
+5.00% (+₹0.98)
Prev. close
₹19.6
Volume
5,250
As of
10 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Vanta Bioscience Limited
Vanta Bioscience Limited, together with its subsidiaries, operates as a preclinical contract research organization in India. The company offers a range of services in method development, validation, impurity profiling, impurity isolation, characterization, certification and evaluation, mammalian and genetic toxicology, drug metabolism, pharmacokinetics, and bio-analysis during the preclinical stage of drug development. It also provides testing services for agrochemicals and chemicals, such as physico-chemical testing; sub-acute, sub-chronic, and chronic; toxicokinetics assessment, CoA and dose formulation analysis, 5 batch analysis, and studies on behavior in water, soil and air, bioaccumulation, as well as acute 6 pack, carcinogenicity, genetic toxicity, DART, eco-toxicity, and alternative to animal studies. In addition, it offers diet formulation services, which include starter material processing, proximate and composition analysis, diet balancing and formulation, irradiation, and packaging and labeling; and batch release pharmacopoeia tests, such as pyrogen testing, stability studies, and abnormal toxicity and impurity profiling. Further, the company provides services to medical device industry including cytotoxicity, intracutaneous/mucous membrane irritation, dermal sensitization, mutagenicity assays, acute systemic toxicity, and implantation tests. Additionally, it is involved in the provision of risk assessment services to evaluate the active pharmaceutical ingredients, excipients, extractable, leachables, and pharmaceutical impurities; and expert services to determine health-based exposure limits for permitted daily exposure or allowable daily exposure, including occupational exposure limits. The company offers its services to pharmaceutical, medical devices, nutraceuticals, feed additive, biotech, agrochemicals, cosmetics, and chemical industries. Vanta Bioscience Limited was incorporated in 2016 and is based in Secunderabad, India.
Details
Sector
Healthcare
Industry
Diagnostics & Research
CEO
Mr. Dopesh Raja Mulakala
Headquarters
Secunderabad
Website
vantabio.comExchange
View on BSE ↗Key stats
Market cap
₹14.64 Cr
P/E ratio (TTM)
137.2
EPS (TTM)
₹0.15
Beta (1Y · daily vs NIFTY 50)
1.17
Beta (5Y · monthly vs NIFTY 50)
0.81
Shares float
11.25 L
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (consolidated), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.0% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide. EBITDA is omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹10.04 Cr | ₹9.69 Cr | ₹6.28 Cr | ₹9.72 Cr | ₹1.13 Cr | ₹1.82 Cr | |
| EBITDA | — | — | ₹-16.09 L | ₹1.39 Cr | ₹-83.82 L | ₹2.02 Cr |
| ₹44.90 L | ₹8.80 L | ₹-6.48 Cr | ₹-2.32 Cr | ₹-2.67 Cr | ₹10.83 L | |
| Diluted EPS | — | ₹0.14 | ₹-10.27 | ₹-3.67 | ₹-4.23 | — |
Depreciation & amortisation, EBITDA, Pretax income, Tax provision, Interest expense, Diluted EPS have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹84.71 Cr | ₹85.40 Cr | ₹85.88 Cr | ₹66.10 Cr | |
| — | — | ₹57.16 Cr | ₹60.95 Cr | ₹70.08 Cr | ₹38.08 Cr | |
| Stockholders' equity | — | — | ₹17.51 Cr | ₹15.20 Cr | ₹10.42 Cr | ₹21.18 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Long-term debt, Current (short-term) debt, Others, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹-62.76 L | ₹2.68 Cr | ₹1.36 Cr | ₹-5.22 Cr | |
| Investing cash flow | — | — | ₹-5.91 Cr | ₹-3.31 Cr | ₹-5.79 Cr | ₹-6.87 Cr |
| — | — | ₹6.41 Cr | ₹69.32 L | ₹4.43 Cr | ₹12.08 Cr | |
| Capital expenditure | — | — | ₹-28.69 Cr | ₹-3.40 Cr | ₹-5.79 Cr | ₹-6.87 Cr |
| End cash position | — | — | ₹9.66 L | ₹16.06 L | ₹14.76 L | ₹13.54 L |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Vanta Bioscience Limited | ₹14.64 Cr | ₹20.58 | 137.2 | 0.69 | 0.5% | 1.80 | +61.1% | -7.9% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.